口服促性腺激素释放激素拮抗剂治疗子宫平滑肌瘤
本文综述口服促性腺激素释放激素(GnRH)拮抗剂联合更年期替代水平类固醇激素或使用避免完全下丘脑抑制的剂量治疗子宫平滑肌瘤的疗效与安全性。口服GnRH拮抗剂快速抑制性激素,避免初始 flare,有效减少肌瘤相关月经过多、改善贫血和疼痛,联合反向添加治疗可减少低雌激素副作用。
要点
- 口服GnRH拮抗剂快速抑制性激素,避免激动剂初始 flare 及症状暂时加重。
- 联合更年期替代水平类固醇激素可减少潮热和骨密度丢失等低雌激素副作用。
- 美国FDA已批准 elagolix 联合方案和 relugolix 联合方案用于肌瘤治疗。
核心结论
- 口服GnRH拮抗剂联合更年期替代水平类固醇激素或使用避免完全下丘脑抑制的剂量,可有效减少肌瘤相关月经过多、改善贫血和疼痛,并适度缩小子宫体积。
- 反向添加治疗可将潮热和骨密度丢失等低雌激素副作用减少至接近安慰剂治疗的水平。
- 基线疾病参数较差似乎不抑制疗效,疗效在广泛临床表现为中显得稳健。
研究设计与样本
- 本文为概述性综述,回顾口服GnRH拮抗剂联合更年期替代水平类固醇激素或使用避免完全下丘脑抑制的剂量治疗子宫平滑肌瘤的疗效与安全性。
主要发现
- 口服GnRH拮抗剂提供性激素的快速抑制,避免 parenteral GnRH 激动剂典型的初始类固醇 flare 及所致症状暂时加重。
- 口服GnRH拮抗剂有效减少肌瘤相关月经过多,伴高闭经率,改善贫血和肌瘤相关疼痛。
- 与更年期替代水平类固醇激素联用时,适度缩小子宫体积。
- 反向添加治疗可将潮热和骨密度丢失等低雌激素副作用减少至接近安慰剂治疗的水平。
- 临床试验参与者 largely 反映了受子宫平滑肌瘤影响的人群。
关键数值与推荐
- 美国食品药品监督管理局(FDA)批准 elagolix 300 mg 每日两次联合每日一次雌二醇(1 mg)和炔诺酮(0.5 mg)用于肌瘤治疗。
- 美国食品药品监督管理局(FDA)批准 relugolix 40 mg 每日一次联合雌二醇(1 mg)和炔诺酮(0.5 mg)联合疗法用于肌瘤治疗。
- Linzagolix 在美国处于研究阶段,但在欧盟已获批两种剂量,伴或不伴类固醇激素使用。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Uterine leiomyomas are common hormone-responsive neoplasms that frequently cause heavy menstrual bleeding, anemia, pelvic pressure, pain, and adverse reproductive outcomes. In this overview, the efficacy and safety of oral gonadotropin-releasing hormone (GnRH) antagonists, co-administered with menopausal replacement-level steroid hormones or used at doses to avoid complete hypothalamic suppression, are reviewed for the management of uterine leiomyomas. Oral GnRH antagonists provide rapid suppression of sex steroids and avoid the initial steroidal flare and resultant temporary worsening of symptoms typically seen with parenteral GnRH agonists. Oral GnRH antagonists are effective in reducing leiomyoma-associated heavy menstrual bleeding, with high rates of amenorrhea and improved anemia and leiomyoma-associated pain, and providing modest reduction in uterine volume when used in combination with menopausal replacement-level steroid hormones. This add-back therapy can reduce hypogonadal side effects, including hot flushes and bone mineral density loss, close to levels seen with placebo therapy. Currently, both elagolix 300 mg twice daily with once-daily estradiol (1 mg) and norethindrone (0.5 mg) and relugolix 40 mg once daily with estradiol (1 mg) and norethindrone (0.5 mg) combination therapy are approved for leiomyoma treatment by the U.S. Food and Drug Administration. Linzagolix is under investigation in the United States but approved at two does with and without steroid hormones in the European Union. The efficacy of these agents appears to be robust over a wide spectrum of clinical presentations, demonstrating that worse disease parameters at baseline do not appear to inhibit efficacy. Across clinical trials, participants largely reflected the population of individuals affected by uterine leiomyomas.
引用
- Neblett MF, Stewart EA. Oral Gonadotropin-Releasing Hormone Antagonists for the Treatment of Uterine Leiomyomas. Obstet Gynecol. 2023. PMID: 37103532. doi:10.1097/AOG.0000000000005145
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。